Clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients: the SUCLINGEN study

Loganadan NK 1 , Huri HZ 1 , Vethakkan SR 2 , Hussein Z 3

Affiliations 

  • 1 Faculty of Pharmacy, University of Malaya, Kuala Lumpur, 50603, Malaysia
  • 2 Division of Endocrinology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia
  • 3 Department of Medicine, Putrajaya Hospital, Precinct 7, Putrajaya, 62250, Malaysia
Pharmacogenomics, 2020 06;21(9):587-600.
PMID: 32468916 DOI: 10.2217/pgs-2019-0171

Abstract

Background: Due to several limitations in the study designs of sulfonylurea pharmacogenomics studies, we investigated the clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients. Materials & methods: Patients receiving the maximum sulfonylurea and metformin doses for >1 year were enrolled. Secondary sulfonylurea failure was defined as HbA1c >7.0% (>53 mmol/mol) after a 12-month follow-up. Results: By multivariate analysis, increased insulin resistance (HOMA2-IR), baseline HbA1c >7.0%, residing in eastern Peninsular Malaysia, and the CC genotype of rs757110 ABCC8 gene polymorphism were independent predictors of secondary sulfonylurea failure (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications